All In Biotech

Drug Trial Radar · NCT05193227

Sustained Release Lidocaine for the Treatment of Postoperative Pain

A Randomized Phase 2 Trial of ST-01 (Sustained-release Lidocaine Polymer Solution for Injection) in Subjects Undergoing Pelvic Surgery

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Oct 27, 2021

Primary completion

Apr 27, 2026

Study completion May 27, 2026

Sponsor

Lead sponsor
University of British ColumbiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sustained Therapeutics Inc.
First posted
Jan 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this study, the investigators are testing a new formulation of lidocaine for its suitability in managing postoperative pain after pelvic (circumcision, inguinal, scrotal), perineal (hemorrhoidectomy) or perianal (fistulotomy) incisions. The new formulation ST-01 is a sustained release lidocaine formulation and is expected to provide pain relief over multiple days. Currently, the drug lidocaine is not available as an injectable slow-release formulation.

Conditions

  • Postoperative Pain
  • Postsurgical Pain

Interventions

  • ST-01Drug

    Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)

  • Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)Drug

    Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate the efficacy of an injection of ST-01 to reduce subject-reported postoperative pain after surgery compared to standard of careTime frame: 3 days

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Vancouver Prostate Centre

    Vancouver, British Columbia, Canada · Recruiting

  • St. Pauls Hospital

    Vancouver, British Columbia, Canada · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.